Transcode Therapeutics Inc Market Cap ($1.69 Million)
Market Cap & Net Worth: Transcode Therapeutics Inc (RNAZ)
Transcode Therapeutics Inc market cap. Transcode Therapeutics Inc (NASDAQ:RNAZ) has a market capitalization of $1.69 Million ($1.69 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30207 globally and #6158 in its home market, demonstrating a -4.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Transcode Therapeutics Inc's stock price $1.60 by its total outstanding shares 1058481 (1.06 Million). Also see Transcode Therapeutics Inc (RNAZ) cash flow conversion for how efficiently the company converts equity into cash flow.
Transcode Therapeutics Inc Market Cap History (2021–2026)
Transcode Therapeutics Inc market cap history from 2021 to 2026. Data shows change from $2.15 Billion to $1.69 Million (-75.98% CAGR). Check RNAZ live share price for real-time trading data and today's change.
Index Memberships
Transcode Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #877 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #2795 of 3165 |
Weight: Transcode Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Transcode Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Transcode Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Transcode Therapeutics Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RNAZ by Market Capitalization
Companies near Transcode Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see Transcode Therapeutics Inc total assets for a full breakdown of the balance sheet.
Key companies related to Transcode Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Transcode Therapeutics Inc (2021–2026)
Market capitalization of Transcode Therapeutics Inc from 2021 to today. Between 2021 and today, Transcode Therapeutics Inc's market cap moved from $2.15 Billion to $ 1.69 Million, with a yearly change of -75.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.69 Million | -76.57% |
| 2025 | $7.23 Million | +102.67% |
| 2024 | $3.57 Million | -48.94% |
| 2023 | $6.99 Million | -98.77% |
| 2022 | $569.89 Million | -73.50% |
| 2021 | $2.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Transcode Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.69 Million USD |
| MoneyControl | $1.69 Million USD |
| MarketWatch | $1.69 Million USD |
| marketcap.company | $1.69 Million USD |
| Reuters | $1.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more